More important, we showed for the first time that amplified TGF-β signaling through increased TβR-II expression [18] was sufficient in subverting the metastatic benefit of FAK chemotherapies, by using the same treatment protocol that was sufficient in reducing the metastasis of wild-type breast cancer cells. The gene discussed is PTK2; the disease is breast carcinoma.